PT-141 (Bremelanotide) Reconstitution and Dosing Math: mg, mL, and Units Explained

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Does PT-141 need to be reconstituted?

Not in its approved form. Vyleesi is a prefilled autoinjector pen containing bremelanotide 1.75 mg, self-injected subcutaneously into the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity [1]. Because the dose is already loaded in the pen, there is nothing to mix and no syringe to fill.

What the approved dosing is

The label directs 1.75 mg subcutaneously, not more than one dose within 24 hours, and states that more than 8 doses per month is not recommended [1]. The efficacy of consecutive doses within 24 hours has not been established, and dosing close together may add to the drug's blood pressure effects [1]. Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1].

What the pen does and does not tell you

Vyleesi's dose is fixed inside the autoinjector [1]. That is the device's design, not a mixing instruction, so the pen cannot be used to work out how many syringe units a vial of any other product would need.

'PT-141' products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [2][1]. Bremelanotide does not appear in any category on FDA's bulk-substance lists [3][4], and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5]. None of that makes a compounded vial an approved product.

What the label says to watch for

Nausea is the dominant reaction: 40.0% on Vyleesi versus 1.3% on placebo across the two 24-week trials in 1,247 premenopausal women, with flushing 20.3% versus 0.3% and headache 11.3% versus 1.9% [1]. Nausea was highest after the first dose (21% of patients) and fell to about 3% with later doses; 8% stopped the trials because of it [1]. Pre-treating with oral ondansetron did not reduce nausea in a 228-woman single-dose study, so the label does not recommend it [1].

Blood pressure rises rather than falls: the label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose, with heart rate down by up to 5 beats per minute and values usually back to baseline within 12 hours [1]. In an 8-day ambulatory study of 127 women, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease [1].

Focal hyperpigmentation was reported by 1% of patients taking up to 8 doses a month versus none on placebo, with higher risk in darker skin and with daily dosing [1]. The overdose section states that nausea, focal hyperpigmentation and more pronounced blood pressure increases are more likely with higher doses [1].